Oric Pharmaceuticals Reports Promising Phase 1b Results for Enozertinib in NSCLC Patients with EGFR Mutations
Reuters
Dec 05
Oric Pharmaceuticals Reports Promising Phase 1b Results for Enozertinib in NSCLC Patients with EGFR Mutations
Oric Pharmaceuticals Inc. announced data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025. The results, which have already been presented, included findings in previously treated non-small cell lung cancer (NSCLC) patients with EGFR atypical mutations and preliminary data in first-line NSCLC patients with EGFR P-loop and alpha C-helix compressing (PACC) mutations. The study reported an 80% overall response rate $(ORR)$ and 100% intracranial ORR in first-line EGFR PACC patients, as well as a 36% ORR in later-line EGFR PACC patients. Enozertinib was reported to have a competitive safety profile with manageable toxicity and a low discontinuation rate. Further enrollment and follow-up in first-line EGFR PACC patients are ongoing at a selected dose, with the next data update expected in mid-2026 ahead of a potential Phase 3 trial.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597449-en) on December 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.